Primary source: Saudi Food and Drug Authority (SFDA)
The SFDA has released Version 4.0 of its regulations, which implements updated definitions, requires that observational Phase IV trials comply with GVP guidelines, mandates consultation for risk minimization studies, and introduces specific requirements for Post-Trial Access Programs effective from 2026-06-28.
These changes will significantly impact clinical trial conduct in Saudi Arabia, ensuring better safety monitoring and alignment with global standards. Failure to comply may result in regulatory penalties or modifications to trial approval.
Ensure compliance with updated SUSAR reporting timelines (15 days), notify SFDA of Phase IV trials within 20 working days post-IRB approval, and prepare for the financial fee of 15,000 Saudi Riyals for clinical trial evaluations.
Regulatory Intelligence Lead
Review before 2026-06-28.
Key changes include: 1) Revision of all definitions to align with global standards; 2) Addition of terms like Biosimilar, Stringent Regulatory Authority (SRA), and Post-Trial Access Program (PTAP); 3) Updated guidance on submissions, waves, and timelines for clinical trial phases; 4) Implementation of a new section on reliance pathways; 5) New requirements for PI-initiated trials; 6) Introduction of the Post-Clinical Trial Access Program with associated forms for clearance requests.
The updated regulation has direct pharmacovigilance impact: 1) It mandates that observational Phase IV trials and registry studies adhere to Good Pharmacovigilance Practices (GVP) guidelines; 2) It requires consultation with the Drug Safety and Risk Management Department for risk minimization studies (RIMS); 3) It provides updated definitions for adverse reactions and Suspected Unexpected Serious Adverse Reactions (SUSARs) in the context of clinical trials; 4) It establishes requirements for Post-Trial Access Programs which may involve ongoing safety monitoring.
Mandatory fees impact budget planning for clinical trials.
Financial fee structure and clinical trial submission processes.
Increased urgency in adverse event reporting.
Mandatory SUSAR reporting timelines.
Additional steps needed for procuring drugs for trials.
Requirements for drug import licenses.
Ensure compliance with updated SUSAR reporting timelines (15 days), notify SFDA of Phase IV trials within 20 working days post-IRB approval, and prepare for the financial fee of 15,000 Saudi Riyals for clinical trial evaluations.
The updated SFDA regulations mandate adherence to Good Pharmacovigilance Practices for Phase IV trials and registry studies, necessitate consultation with the Drug Safety and Risk Management Department for risk minimization studies, and establish requirements for a Post-Trial Access Program. This update also refines definitions related to adverse reactions in clinical trials.
What changed: The SFDA has released Version 4.0 of its regulations, which implements updated definitions, requires that observational Phase IV trials comply with GVP guidelines, mandates consultation for risk minimization studies, and introduces specific requirements for Post-Trial Access Programs effective from 2026-06-28.
Why it matters: These changes will significantly impact clinical trial conduct in Saudi Arabia, ensuring better safety monitoring and alignment with global standards. Failure to comply may result in regulatory penalties or modifications to trial approval.
Practical implication: Ensure compliance with updated SUSAR reporting timelines (15 days), notify SFDA of Phase IV trials within 20 working days post-IRB approval, and prepare for the financial fee of 15,000 Saudi Riyals for clinical trial evaluations.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
